Listed by the USPTO as DEBERRY, REGINA M
Tech Center 1600 • Art Units: 1628 1647 1674 1677
This examiner grants 50% of resolved cases
DEBERRY, REGINA M has resolved 605 cases in Tech Center 1600 and Art Unit 1628. The allowance rate is 50.2%, while the interview lift is 30.7%. The median time to allowance is 1237 days. The figures show an allowance rate near one-half of resolved cases and a substantially larger measured association with interviews than the allowance rate alone would suggest.
The listed companies are Hoffmann-La Roche Inc., Arizona Board of Regents on Behalf of Arizona State University, and The Regents of the University of California. The listed firms are FOLEY & LARDNER LLP, SUGHRUE MION, PLLC, and Clark+Elbing LLP - Genentech and Roche. Counsel working in this docket can draw on the identified biotechnology and institutional prosecution history when developing interview and response strategies.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18629145 | METHOD AND DEVICE FOR DETECTING SIGLEC12 | Non-Final OA | The Regents of the University of California |
| 18645245 | Method for purifying PEGylated erythropoietin | Final Rejection | Hoffmann-La Roche Inc. |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 17640293 | THERAPEUTIC FUSION PROTEINS | Non-Final OA | NOVARTIS AG |
| 19542772 | ANTI-INTERLEUKIN-11 ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17773886 | HIGH SALT LOAD CONDITIONING DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES | Final Rejection | AMGEN INC. |
| 18032080 | FORMULATION FOR WOUND HEALING | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18041123 | METABOLISM-BASED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF TREATMENT | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 17782469 | STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18477010 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND DENDRITIC CELLS | Non-Final OA | Novocure GmbH |
| 17327504 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR | Final Rejection | SANOFI BIOTECHNOLOGY |
| 18030983 | COMPOSITIONS FOR TREATMENT ALOPECIA AREATA, BIOMARKERS FOR TREATMENT SUCCESS AND, METHODS OF USE THEREOF | Non-Final OA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18682310 | METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17794724 | PHASE SEPARATION SENSORS AND USES THEREOF | Non-Final OA | THE ROCKEFELLER UNIVERSITY |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Final Rejection | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.2% of resolved applications examined by Regina M Deberry were allowed (605 resolved cases), compared with 25.9% across Art Unit 1628 over the last five years.
This examiner's interview lift is +30.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Regina M Deberry took 1,237 days on average from filing to allowance.
Regina M Deberry examines applications in Art Unit 1628 in Tech Center 1600 (Biotechnology & Pharmaceuticals).